Azurity Pharmaceuticals announces that the US FDA has approved Konvomep (omeprazole and sodium bicarbonate for oral suspension). Konvomep is approved for the treatment of active benign gastric ulcer and the reduction of risk of upper gastrointestinal bleeding in critically ill patients.

• Azurity Pharmaceuticals, Inc
  For more information, visit pppmag.com/info